Elektronisk udgave - Sundhedsstyrelsen

3. Burnham JA,Wright RR, Dreisbach J, Murray RS.The effect of high-dose steroids on MRIgadolinium enhancement in acute demyelinating lesions.Neurology 1991;41:1349-54.4. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes ingadolinium-DTPA enhancement after high-dose intravenous methylprednisolone inmultiple sclerosis. Neurology 1991;41:1219-22.5. Miller DH,Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF,McDonald WI. High dose steroids in acute relapses of multiple sclerosis: MRI evidencefor a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry1992;55:450-3.6. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dosemethylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol NeurosurgPsychiatry 1987;50:511-6.7. Beck RW, Cleary PA, Anderson MMJ, Keltner JL, Shults WT, Kaufman DI, Buckley EG, CorbettJJ, Kupersmith MJ, Miller NR, et al. A randomized, controlled trial of corticosteroidsin the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med1992;326:581-8.8. Barnes MP, Bateman DE, Cleland PG, Dick DJ,Walls TJ, Newman PK, Saunders M,Tilley PJ.Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol NeurosurgPsychiatry 1985;48:157-9.9. Panitch HS. Interferons in multiple sclerosis. A review of the evidence. Drugs1992;44:946-62.10. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationshipto disease activity. Arch Neurol 1992;49:265-70.11. Olsson T. Role of cytokines in multiple sclerosis and experimental allergic encephalomyelitis.Eur J Neurol 1994, 1:7-19.12. Weinstock Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biologicaleffects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.13. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patientstreated with gamma interferon. Lancet 1987;1:893-5.14. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis withgamma interferon: exacerbations associated with activation of the immune system.Neurology 1987;37:1097-102.15. AUSTIMS Research Group. Interferon-alpha and transfer factor in the treatment of multiplesclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry1989;52:566-74.16. Kastrukoff LF, Oger JJ, Hashimoto SA, Sacks SL, Li DK, Palmer MR, Koopmans RA, PetkauAJ, Berkowitz J, Paty DW. Systemic lymphoblastoid interferon therapy in chronic progressivemultiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990;40:479-86.17. Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GP, Huddlestone JR, Francis GS, HooperCK, Kamin Lewis RM, Johnson KP, et al. Systemic alpha-interferon therapy of multiplesclerosis. Neurology 1984;34:1273-9.18. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S,Geuna M, et al. Chronic systemic high-dose recombinant interferon alfa-2a reducesexacerbation rate, MRI signs of disease activity, and lymphocyte interferon gammaproduction in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-13.19. Nyland H, Myhr KM, Lillas F, Smievoll AI, Riise T, Nortvedt M, Nilsen R. Treatment ofrelapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a:design of a randomised, placebo-controlled, double blind trial in Norway. Mult Scler1996; 1:372-375.20. Arnason BG. Interferon beta in multiple sclerosis. Neurology 1993;43:641-3.21. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Josefowicz R, Cuetter A, HusainF, Smith WA, Ekes R, et al. Multicentre double-blind study of effect of intrathecally administerednatural human fibroblast interferon on exacerbations of multiple sclerosis.Lancet 1986;2:1411-3.110